Delbert G Robinson
Overview
Explore the profile of Delbert G Robinson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
98
Citations
3573
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Thies M, DeRosse P, Sarpal D, Argyelan M, Fales C, Gallego J, et al.
Schizophr Bull Open
. 2020 Aug;
1(1):sgaa014.
PMID: 32803161
Antipsychotic (AP) medications are the mainstay for the treatment of schizophrenia spectrum disorders (SSD), but their efficacy is unpredictable and widely variable. Substantial efforts have been made to identify prognostic...
12.
Kane J, Schooler N, Marcy P, Correll C, Achtyes E, Gibbons R, et al.
JAMA Psychiatry
. 2020 Jul;
77(12):1217-1224.
PMID: 32667636
Importance: Long-acting injectable antipsychotics (LAIs) can potentially reduce hospitalization risk by enhancing medication adherence but are rarely considered for early-phase schizophrenia treatment. Objective: To determine whether encouraging use of a...
13.
Schoretsanitis G, Kane J, Correll C, Marder S, Citrome L, Newcomer J, et al.
J Clin Psychiatry
. 2020 May;
81(3).
PMID: 32433836
Objective: The quantification of antipsychotic levels in blood, also known as therapeutic drug monitoring (TDM), is a potentially useful tool of modern personalized therapy that can be applied to augment...
14.
Robinson D, Subramaniam A, Fearis P, Shi R, Walsh M, Hanna L, et al.
Psychiatr Serv
. 2019 Dec;
71(4):337-342.
PMID: 31847736
Objective: The authors designed this project to identify barriers to using long-acting formulations of antipsychotics. Methods: The authors used a focused ethnographic approach. Patients, psychiatrists, nurses, therapists and administrators were...
15.
Homan P, Argyelan M, Fales C, Barber A, DeRosse P, Szeszko P, et al.
Neuropsychopharmacology
. 2019 Jul;
44(11):1948-1954.
PMID: 31315130
Second-generation antipsychotic drugs (SGAs) are essential in the treatment of psychotic disorders, but are well-known for inducing substantial weight gain and obesity. Critically, weight gain may reduce life expectancy for...
16.
Robinson D, Schooler N, Rosenheck R, Lin H, Sint K, Marcy P, et al.
Psychiatr Serv
. 2019 May;
70(7):569-577.
PMID: 31084291
Objective: Despite treatment advances in other domains, inpatient psychiatric hospitalization rates for individuals with first-episode psychosis remain high. Even with early intervention services, a third or more of individuals are...
17.
Kane J, Schooler N, Marcy P, Achtyes E, Correll C, Robinson D
J Clin Psychiatry
. 2019 May;
80(3).
PMID: 31050233
Objective: To document the acceptability of treatment with long-acting injectable (LAI) antipsychotic medication to early-phase schizophrenia patients as demonstrated by enrollment in a cluster-randomized LAI clinical trial. Methods: Eligible patients...
18.
Homan P, Argyelan M, DeRosse P, Szeszko P, Gallego J, Hanna L, et al.
Neuropsychopharmacology
. 2019 Jan;
44(5):915-922.
PMID: 30679724
Despite recent advances, there is still a major need for prediction of treatment success in schizophrenia, a condition long considered a disorder of dysconnectivity in the brain. Graph theory provides...
19.
Achtyes E, Ben-Zeev D, Luo Z, Mayle H, Burke B, Rotondi A, et al.
Schizophr Res
. 2018 Dec;
206:200-208.
PMID: 30551981
Introduction: Technology-delivered healthcare interventions may enhance dissemination of evidence-based treatments in low-resource areas. These interventions may be accessed 'on-demand,' including after hours. Patients with schizophrenia do engage with technological aids...
20.
Robinson D, Gallego J, John M, Hanna L, Zhang J, Birnbaum M, et al.
Schizophr Res
. 2018 Sep;
204:295-303.
PMID: 30241990
Omega-3 treatment studies for multi-episode schizophrenia or clinical high risk for conversion to psychosis states have had variable, and often negative, results. To examine adjunctive omega-3 treatment for recent onset...